**Research Article**

**PKCδ Promotes High Glucose Induced Renal Tubular Oxidative Damage via Regulating Activation and Translocation of p66Shc**

Panai Song, Shikun Yang, Li Xiao, Xiaoxuan Xu, Chengyuan Tang, Yuyan Yang, Mingming Ma, Jiefu Zhu, Fuyou Liu, and Lin Sun

Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410000, China

Correspondence should be addressed to Lin Sun; zndxsunlin11@163.com

Received 11 May 2014; Revised 30 July 2014; Accepted 10 August 2014; Published 13 October 2014

Academic Editor: Antonio Ayala

Copyright © 2014 Panai Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD). Renal tubular injury by overproduction of ROS in mitochondria plays a critical role in the pathogenesis of DKD. Evidences have shown that p66Shc was involved in renal tubular injury via mitochondrial-dependent ROS production pathway, but little is known about the upstream signaling of p66Shc that leads to tubular oxidative damage under high glucose conditions. In this study, an increased PKCδ and p66Shc activation and ROS production in renal tissues of patients with diabetic nephropathy were seen and further analysis revealed a positive correlation between the tubulointerstitial damage and p-PKCδ, p-p66Shc, and ROS production. In vitro, we investigated the phosphorylation and activation of p66Shc and PKCδ during treatment of HK-2 cells with high glucose (HG). Results showed that the activation of p66Shc and PKCδ was increased in a dose- and time-dependent manner, and this effect was suppressed by Rottlerin, a pharmacologic inhibitor of PKCδ. Moreover, PKCδ siRNA partially blocked HG-induced p66Shc phosphorylation, translocation, and ROS production in HK-2 cells. Taken together, these data suggest that activation of PKCδ promotes tubular cell injury through regulating p66Shc phosphorylation and mitochondrial translocation in HG ambient.

1. **Introduction**

Diabetic kidney disease (DKD) is a leading cause of morbidity and mortality, and it invariably results in an end-stage renal disease (ESRD) [1, 2]. More recently, it has been increasingly documented that the renal tubular injury plays an integral role in the pathogenesis of DKD. In addition, tubulointerstitial lesions are found to be the early and independent features of DKD [3, 4]. Tubular cells injury involves complex etiological and pathophysiological processes. Growing evidence has shown that reactive oxygen species- (ROS-) mediated damage plays a key role in this pathogenesis process affecting renal tubular cells [5–7].

Mitochondrial electron transport chain is the main source of intercellular ROS production [8]. It has been well established that mitochondrial dysfunction participates in the pathological change in tubular injury in DKD [9]. p66Shc, an adaptor protein, is involved in regulation of cellular responses to oxidative stress [10] and is recognized as a new mediator of mitochondrial dysfunction in renal tubular cells under oxidative stress [11–13]. Recent studies demonstrated that p66Shc is phosphorylated at Ser36 residue by apoptosis stimuli and then translocates to the mitochondrial intermembrane space to oxidize cytochrome c, which causes excessive generation of ROS in mitochondria and leads to mitochondrial depolarization [8]. Previous studies in our laboratory have shown that overexpression of a dominant-negative mutant p66Shc (p66Shc S36A) or p66Shc siRNA attenuated or reversed ROS production of mitochondria and cells apoptosis in HK-2 cells, after exposure to angiotensin II or high glucose (HG) ambience [12]. In addition, Pinton et al. [14] found that protein kinase C (PKC)δ, an isofrom of protein kinase C, could induce phosphorylation of p66Shc and triggers mitochondrial accumulation of the protein following activation by oxidative stress. However, whether other isoforms of PKC are also activated and induce mitochondrial translocation of p66Shc in HK-2 cells induced by HG remains unclear.
PKCδ is another pivotal member of protein kinase C, a super-family of serine/threonine kinases, which are involved in many signaling pathways to regulate growth, metabolism, differentiation, and apoptosis. PKCδ is widely expressed in mammalian tissues, including epithelium, placenta, uterus, brain, and kidney [15], and regulates apoptosis in response to a variety of stimuli including hydrogen peroxide (H₂O₂), HG, ultraviolet (UV) radiation, anticancer agents, and ROS [10, 16]. What is more, tyrosine phosphorylation and intracellular translocation of PKCδ are responsible for its proapoptotic role in cell oxidative damage state [17, 18]. It is very interesting that the phosphorylated PKCδ can bind to p66Shc in COS-7 cells induced by H₂O₂ stimulation, which may play a critical role in the oxidative stress signaling pathway [19]. Hence, we speculate that PKCδ may associate with p66Shc and participates in oxidative damage in renal tubular cells in DKD. However, the role of PKCδ on p66Shc activation and mitochondrial translocation in HK-2 cell exposed to HG is not fully understood. In this study, we aimed to assess the expression of p-p66Shc and p-PKCδ in renal tissues of patients with DKD and analyzed the relationship between their expressions and kidney oxidative injury in vivo. We also assessed the role of PKCδ in regulating p66Shc activation and mitochondrial translocation in HK-2 cells induced by HG.

2. Materials and Methods

2.1. Main Reagents and Materials. Human proximal tubular epithelial cells (HK-2) were purchased from ATCC American. Antibodies were obtained from the following sources: polyclonal anti-PKCδ and polyclonal anti-phospho-PKCδ-Tyr-311 from Cell Signaling Technology (Boston, MA) and monoclonal anti-p66Shc and monoclonal anti-phospho-p66Shc-S36 from Abcam (USA). All secondary antibodies for Western blot analysis were from ZSGB-BIO (Beijing, China), and secondary antibodies for immunofluorescence were from Jackson ImmunoResearch (West Grove, PA). Rottlerin was obtained from Enzo life sciences (USA), mitochondria isolation kit was purchased from Beyotime (Jiangsu, China), 4',6-diamidino-2-phenylindole 9 (DAPI) was from Sigma Aldrich (St. Louis, MO), PKCδ siRNA (h) was from Santa Cruz (Santa Cruz, USA), Lipofectamine 2000 and MitoSOX were obtained by Santa Cruz (Santa Cruz, USA) and DAB kit was from CWBIO (Beijing, China). Other reagents, including DMEM medium with low glucose (1000 mg/L), bovine serum albumin (FBS), and trypsin, were obtained from Gibco (USA).

2.2. Morphological Evaluation of Kidney. Human renal biopsy tissues from 32 cases (16 with DN and 16 with minimal change nephropathy) were studied by special stain (PAS and PASM) to assess glomerular, tubulointerstitial pathological change. A semiquantitative scoring system was used to evaluate the severity of tubulointerstitial injury [20, 21]. The human experimental protocols as described above were approved in advance by the Institutional Human Experimentation Ethics Committee, The Second Xiangya Hospital, Central South University.

2.3. Immunohistochemistry (IHC). Renal tissue sections for immunostaining were deparaffinized, rehydrated, and blocked with 3% H₂O₂ solution, followed by antigen retrieval in a microwave oven. The sections were then incubated with antibodies directed against phospho-PKCδ-Tyr-311 (1:50) and phospho-p66Shc-Ser36 (1:100), respectively, and visualized by using a DAB detection kit according to the manufacturer's instructions. Slides were mounted with coverslip and examined with a Zeiss fluorescence microscope. Intracellular generation of O₂⁻ was assessed by DHE staining.

2.4. HK-2 Cell Culture and Treatment. HK-2 cells were cultured in DMEM medium supplemented with 10% FBS, penicillin 1 × 10⁵ U/L, and streptomycin 100 mg/L and incubated at 37°C in a 5% CO₂ environment until the cells were 80% confluent. Cells were then incubated in DMEM medium without FBS for 24 hrs. HK-2 cells were cultured with different concentrations of D-glucose (5 mM–30 mM) for 24 hrs or with 30 mM D-glucose only for indicated time points (0 min–180 min); then, the expression of PKCδ and p66Shc and phosphorylation of both PKCδ (p-PKCδ) and p66Shc (p-p66Shc) were detected by western blotting and immunofluorescence, respectively. In addition, the effect of PKCδ on the phosphorylation and mitochondrial translocation of p66Shc in HK-2 cells exposed to HG was also observed by isolation of mitochondria from HK-2 cells for Western blot analysis.

2.5. Small Interfering RNA for PKCδ. Human small interfering RNA (siRNA) for PKCδ and scrambled siRNA were obtained by Santa Cruz (Santa Cruz, USA). The targeted sequences to silence the transcription of human PKCδ were 5'-GUC UGG UAA GAC UGG AGU ACC-3'. The PKCδ siRNA (final concentration at 20 nM) and scrambled siRNA were transfected into the HK-2 cells according to manufacturer's instructions.

2.6. Western Blot Analysis. The total protein of HK-2 cells was extracted with RIPA lysis buffer which contains protease inhibitors. Following the vendor's instructions, mitochondrial and cytosolic proteins were individually isolated from HK-2 cells by using a mitochondrial isolation kit. The protein expressions of total p66Shc and PKCδ as well as p-p66Shc and p-PKCδ were assessed using anti-p66Shc, anti-PKCδ, anti-p-p66Shc (Ser36 site), and anti-p-PKCδ (Tyr311 site). The antimitochondrial Cox IV antibody was used as loading controls for mitochondrial fractions. The anti-β-actin was used for loading controls of cytoplasmic fractions. Western Blot Kit (with HRP conjugated rabbit or mouse secondary antibody) was used for visualizing the bands.

2.7. Immunofluorescence Staining. For cell staining, HK-2 cells were seeded on glass slides. Cells were fixed with 4% paraformaldehyde (PFA) for 15 min and then washed in PBS (three times, 5 min each). For staining of p-p66Shc and p-PKCδ, cells were treated with 0.1% Triton X-100 for 10 minutes and with blocking buffer containing 10%
Figure 1: Increased p-PKC\(\delta\) and p-p66Shc expression and ROS production in renal tissues of patients with diabetic nephropathy (DN). Renal biopsy samples were collected from 16 of DN patients and 16 of non-DN patients. Tubular atrophy and interstitial fibrosis were seen in renal biopsies in patients with DN as detected by PASM and PAS staining (panels (B) and (D) versus panels (A) and (C)). Immunohistochemical studies revealed increased expression of p-PKC\(\delta\) and p-p66Shc in DN patients (panels (F) and (H) versus panels (E) and (G)) (magnification ×200). Status of oxidant stress in kidneys of DN and non-DN patients indicated in panels (I) and (J). (b) and (c) Averaged relative intensity following staining of anti-p-PKC\(\delta\) and anti-p-p66Shc antibody of renal biopsies of DN patients versus non-DN patients. (d) Relative fluorescence intensity of dihydroethidium (DHE) in kidneys of DN and non-DN patients. (e) Tubular interstitial damage score in DN patients versus non-DN patients. (f) Table shows correlation between p-PKC and p-p66Shc expression, DHE level, and tubular interstitial damage. Values are means ± SEM, *\(P<0.01\).

normal goat serum for half an hour at room temperature, and then the cells were incubated in primary antibody solution overnight (anti-p-p66Shc, 1:50, and anti-p-PKC\(\delta\), 1:100). Fluorochrome-conjugated secondary antibodies (diluted 1:400 in PBS containing 5% BSA) were used for incubating cells for 1 hour at room temperature. DAPI was used to stain the nuclei.

2.8. Detection of Intracellular H\(_2\)O\(_2\) and Assessment of Mitochondrial Superoxide Anion (O\(_2^-\)). The dichlorofluorescein diacetate (DCFH-DA), a H\(_2\)O\(_2\)-sensitive fluorescence probe, was applied to assess the intracellular H\(_2\)O\(_2\), as previously discussed [8, 22]. MitoSOX Red (Invitrogen), a live-cell permeant dye that rapidly and selectively targets mitochondria, was used to observe mitochondrial O\(_2^-\)\(^{•}\). The DCFH-DA fluorescence (with excitation at 490 nm and emission at 520 nm) and MitoSOX red fluorescence (with excitation at 510 nm and emission at 585 nm) were detected in a laser scanning confocal microscope equipped with band-pass filter (Zeiss LSM 510; Carl Zeiss, Thornwood, NY). After staining with DCFH-DA and MitoSOX Red, intracellular H\(_2\)O\(_2\) and mitochondrial O\(_2^-\)\(^{•}\) were also detected by FACS analysis [22].

2.9. Data Analysis. Statistical analysis was carried out using the SPSS16.0 software. The experimental results were expressed as mean values ± standard error of the mean (SEM). One-way ANOVA was used to analyze the differences among groups, and two-tailed \(P\) values are reported. A value of \(P<0.05\) was considered statistically significant.
3. Results

3.1. Increased p-PKCδ and p-p66Shc Expression and ROS Production in Renal Tissues of Patients with Diabetic Nephropathy (DN).

PAMS and PAS staining revealed obvious changes in the morphology of both glomerular and tubulointerstitial compartments; they included focal tubular atrophy and interstitial fibrosis in DN patients (Figure 1(a))((A)–(D)) and Figure 1(e)). IHC staining revealed notable increased p-PKCδ and p-p66Shc expression in the renal tubules of patients with DN (Figure 1(a))((E)–(H)). In addition, the staining intensity was also increased by >60% in DN patients, as assessed by semiquantitative analyses (Figures 1(b) and 1(c)). ROS production was detected by using ROS-sensitive vital dye dihydroethidium, which revealed increased ROS generation in kidney tissues of DN patients (Figure 1(a))((I)–(J)) and Figure 1(d)). Further analysis revealed a positive correlation between the tubulointerstitial damage and p-PKCδ and p-p66Shc expression and ROS production (Figure 1(f)).

3.2. HG Induced Phosphorylation of PKCδ and p66Shc in HK-2 Cells.

HK-2 cells were exposed to different concentrations of D-glucose (5 mM–45 mM) for 120 min; then, protein expression and phosphorylation of PKCδ and p66Shc were determined by Western blotting analyses. As shown in Figure 2(a), there was no obvious change in protein expression of total PKCδ and p66Shc [middle panels], while the phosphorylated PKCδ (Tyr311) and p66Shc (Ser36) were significantly increased in a dose-dependent manner in HK-2 cells treated with HG (upper panels). In addition, HK-2 cells were treated with D-glucose (30 mmol/L) for various times (0 min–180 min). Results indicated that HG induced the phosphorylation of p66Shc (Ser36) and PKCδ (Tyr311) in a time-dependent manner within 15 min and expression was sustained for 180 min (Figure 3(a), upper panels). However, no change was observed in total PKCδ and p66Shc expression (Figure 3(a), middle panels).

3.3. Inhibition of HG-Induced p66Shc Phosphorylation in HK-2 Cells by Rottlerin.

To investigate whether PKCδ is involved in the activation of p66Shc in HK-2 cells with HG, we initially investigated the toxic effects of Rottlerin, a pharmacologic inhibitor of PKCδ, since it has been reported that Rottlerin is toxic to the rat kidney proximal tubular cells when exposed to more than 5.0 μM concentration [23]. We examined the effects of Rottlerin with lower concentrations (0.5 to 4.0 μM) on HK-2 cells prior to 30 mM D-glucose treatment and found...
that HG induced PKCδ activation and it was notably suppressed by Rottlerin in a dose-dependent manner (data not shown). In order to reduce the potential toxicity of Rottlerin to HK-2 cells, we chose 1 μM Rottlerin for this study. We found that 1 μM Rottlerin could significantly inhibit p66Shc phosphorylation in HK-2 cells treated with HG (Figure 4(a), upper panel, lane 3 versus lane 2). No change was seen in the total p66Shc expression (middle panel). Similar results were also observed by cells immunofluorescence staining. As shown in Figure 4(c), HG also increased the phosphorylation of PKCδ and p66Shc, while this effect was abolished with the treatment of Rottlerin. These data suggested that PKCδ may be involved in HG-induced p66Shc phosphorylation.

3.4. Inhibition of HG-Induced p66Shc Phosphorylation in HK-2 Cells by PKCδ siRNA. To further ascertain that PKCδ is involved in p66Shc phosphorylation in response to HG stimulation, we used RNAi method to knock down endogenous PKCδ in HK-2 cells. With PKCδ siRNA treatment a marked decrease of p66Shc phosphorylation was seen in the HK-2 cells subjected to HG treatment (Figure 5, lane 4 versus lane 2). No change was found in the levels of p66Shc phosphorylation in HK-2 cells treated with PKCδ siRNA compared to that of control siRNA treatment (lane 3 versus lane 1). These results confirmed that PKCδ participated in the phosphorylation of p66Shc in HK-2 cells treated with HG.

3.5. PKCδ Modulates the Mitochondrial Translocation of p66Shc in HK-2 Cells in Response to HG Stimulation. To investigate the mechanisms by which mitochondrial translocation of p66Shc occurs, cells transfected with PKCδ siRNA or scrambled siRNA were exposed to 30 mM D-glucose for different time intervals (0 min–180 min). The cytosolic and mitochondrial fractions were then isolated from HK-2 cells for Western blot analysis. As shown in Figure 6(a), compared with control (5 mM D-glucose), markedly increased phosphorylation of p-p66Shc in a time-dependent manner was observed in the cytosolic fractions of HK-2 cells treated by HG (Figure 6(a) upper panels, lanes 2–4 versus lane 1, and Figure 6(b)), while this effect was suppressed by treatment with PKCδ siRNA (Figure 6(a) upper panels, lanes 5–7 versus lanes 2–4, and Figure 6(b)). In contrast, the expression of p66Shc was also increased in time-dependent manner in mitochondrial fractions isolated from HK-2 cells treated by HG (Figure 6(a) middle panels, lanes 2–4 versus lane 1, and Figure 6(c)), while this effect was abolished with the treatment of PKCδ siRNA (Figure 6(a) middle panels, lanes 5–7 versus lanes 2–4, and Figure 6(c)). Together, the results suggest that the phosphorylation of p66Shc and its
Figure 4: Rottlerin inhibits HG-induced p66Shc phosphorylation in HK-2 cells. Cells were treated with Rottlerin for 30 min prior to HG (30 mM) treatment. Total proteins were collected for Western blot analysis of p-p66Shc, total p66Shc, and β-actin ((a) and (b)). (c) By immunocytofluorescence microscopy, the increased phosphorylation of PKCδ and p66Shc was seen in HK-2 cells after treatment with 30 mM HG, while this effect was significantly attenuated in Rottlerin group. Values are means ± SEM, N = 3. *P < 0.01 versus LG group, #P < 0.01 versus HG-only group.

Figure 5: PKCδ siRNA inhibits HG-induced p66Shc phosphorylation in HK-2 cells. HK-2 cells were transfected with either PKCδ siRNA or scrambled siRNA and then stimulated with 30 mM HG for 24 hrs. PKCδ, p66Shc, and p-p66Shc were detected by Western blot analysis. An increased expression of p-p66Shc was observed in HK-2 cells induced by HG, but it failed in the group treated with PKCδ siRNA. Values are means ± SEM, N = 4. *P < 0.01 versus LG group, †P < 0.01 versus scrambled siRNA.
mitochondrial translocation in response to HG stimulation is dependent on activity of PKCδ.

3.6. PKCδ siRNA Attenuates the Generation of Intracellular ROS and Mitochondrial Superoxide in HK-2 Cells Subjected to HG. By confocal microscopy, cells stained with DCFH-DA revealed an increase in intracellular ROS production in HK-2 cells treated with HG, while it was reduced with the treatment of PKCδ siRNA (Figure 7(a), upper panel). In addition, to measure mitochondrial superoxide (O$_2^•$−), the MitoSOX Red probe was used. Results showed that HG also increased the mitochondrial O$_2^•$− generation, which was also markedly reduced with the treatment of PKCδ siRNA (Figure 7(a), lower panel). Similar results were observed by FACS analyses (Figures 7(b) and 7(c)).

4. Discussion

The number of pathways and molecules participating in the progression of DKD has been reported, and it is believed that renal proximal tubular cell oxidative damage and apoptosis with the overproduction of ROS are associated with the early stages of DKD [5], and this plays a key role in the progression of DKD [24]. p66Shc is a vital adaptor protein that regulates oxidative stress and lifespan in mammals cells, and genetic deletion of p66Shc can attenuate hyperglycemia-induced endothelial dysfunction and oxidative damage [25, 26]. Vashistha and Meggs [27] found that p66 null Akita mice have marked attenuation of oxidative stress and glomerular/tubular injury and distinct reduction in urine albumin excretion. This finding indicates that p66Shc-mediated oxidative stress plays a central role in renal oxidative injury of DKD. However, detailed molecular mechanism of p66Shc activation and its mitochondrial translocation in this process need be further addressed.

It is known that p66Shc and its activity are significantly increased in both kidneys of STZ-induced diabetic mice and db/db mice, a type 2 diabetic mice model, which are associated with increased oxidative damage [12]. Moreover, PKCβ can be activated by hyperglycemia and oxidative stimulus in renal tubular cells and it is accompanied with phosphorylation of p66Shc [8, 14, 28], and inhibition of PKCβ could partially prevent p66Shc phosphorylation and
its mitochondrial translocation in HK-2 cells treated with HG [12]. Furthermore, increased evidence indicates that inhibition of PKCβII activation prevents phosphorylation of p66Shc in human aortic endothelial cells exposed to hyperglycemic stress or oxidized low-density lipoprotein and protects mice from gut I/R injury by suppressing the adaptor p66Shc mediated oxidative stress [29–31]. These data indicate that PKCβII is an important protein that mediates the phosphorylation of p66Shc in diabetic nephropathy. However, whether other PKC members are also involved in this process is still unknown.

This study demonstrates a significant role for PKCδ in tubular cell oxidative damage under hyperglycemic states. First, we discovered that both p66Shc phosphorylation and PKCδ phosphorylation were increased in renal proximal tubules of patients with DKD compared with non-DN patients, which apparently induce increased oxidative damage to the tissues (Figure 1). These results support our previous hypothesis: there is a close relationship between the phosphorylation of p66Shc and PKCδ activation, and here we further confirmed it by in vitro studies. Results showed that PKCδ activation was accompanied with the phosphorylation of p66Shc induced by HG in HK-2 cells (Figures 2 and 3), which is consistent with the results reported by Liu et al. [32] that tyrosine phosphorylation of PKCδ can be induced by HG in neural precursor cells. These results indicate that HG can induce activation of PKCδ, and p66Shc phosphorylation may be associated with PKCδ.

Recent evidence [33] indicates that the formation of PKCδ/p66Shc/Cyt.C complex plays a significant role in cellular oxidative damage mediated by PKCδ. Knocking out any of these genes will disrupt the signaling pathways of oxidative damage. In addition, Morita et al. [19] have discovered that Tyr331 of PKCδ was phosphorylated by epidermal growth factor receptor (EGFR) in COS-7 cells with the stimulation of H2O2, and then it bound with p66Shc and EGFR to form a complex, which played an important role in oxidative stress. Therefore, we speculated that PKCδ may play a potential role in tubular cell oxidative damage with p66Shc involvement under HG ambience. In this study, we demonstrated that treatment with Rottlerin, a specific blocker of PKCδ, markedly suppressed HG-induced p66Shc phosphorylation (Figure 4). Although Rottlerin has been used in many researches to clarify the role of PKCδ in a variety of cellular events, it also inhibits many other protein kinases including p38-regulated/activated kinase,
calmodulin-dependent protein kinase III, and mitogen-activated protein kinase-activated protein kinase 2 [15, 34]. Therefore, to assess the role of PKCδ in p66Shc phosphorylation, knockdown of endogenous PKCδ with RNAi was used in HK-2 cells. Results indicated that PKCδ siRNA partially blocked HG-induced p66Shc phosphorylation (Figure 5) and its mitochondrial translocation (Figure 6). Thus, our data strongly indicated that PKCδ could modulate p66Shc phosphorylation and its mitochondrial translocation in HK-2 cells exposed to HG ambience. In addition, a study by Lin et al. [35] revealed that PKCδ-knockdown selectively decreased expression of PKCβII in human macrophages. This data indicated that there may be potential interactions and regulations between PKCδ and PKCβII. Here we demonstrated that PKCδ could induce the phosphorylation of p66Shc in HK-2 cells exposed to HG; whether or not PKCδ is involved in this process by regulating PKCβII needs to be further studied in future.

Accumulating evidence indicates that PKCδ is responsible for elevated intracellular ROS production in HF adipocytes, which is mediated by high glucose and NADPH oxidase [36]. Moreover, PKCδ knockout mice reveal reduced ROS formation, and they were resistant to cell death induced by different stimuli [37]. To address whether PKCδ participates in the intracellular ROS production by regulating p66Shc phosphorylation and mitochondrial translocation in HK-2 cells following the treatment of HG, DCFH-DA, a dye probe that measures ROS (H₂O₂) in the cytosol, and MitoSOX, a mitochondrial superoxide (O₂⁻) indicator, were employed. As elucidated in Figure 7, HG increased intracellular ROS production as well as mitochondrial O₂⁻ generation, and this effect was blocked by overexpression of PKCδ siRNA. These observations support that PKCδ plays a crucial role in HG-induced mitochondrial ROS production mediated by p66Shc. Furthermore, it has been reported that phosphorylation of p66Shc induced by PKCβ under oxidative stress states could be isomerized by prolyl isomerase (Pin1), and then it might be dephosphorylated by PP2A. After dephosphorylation, p66Shc translocates into mitochondria, promoting the ROS generation [14]. However, recent studies [38, 39] have suggested that activation of PKCδ by oxidative stress results in its mitochondrial translocation, leading to release of cytochrome c and the induction of apoptosis. In addition, Leitges et al. [40] have reported that phosphorylated

Figure 8: Schematic drawing depicting PKCδ mediates p66Shc phosphorylation and mitochondrial translocation induced by HG. With treatment of HG, PKCδ is activated, promoting p66Shc phosphorylation and its translocation to mitochondria, where p66Shc oxidizes mCyt.C to induce mitochondrial ROS generation, which results in oxidative damage and apoptosis of renal tubular epithelial cells.
PKCδ binds to the SH2 domain of Shc isoforms in antigen-stimulated mouse bone marrow-derived mast cells. These discoveries indicate that activation of PKCδ can lead to phosphorylation of p66Shc and may form a complex with p66Shc, which then translocates to mitochondria. Nevertheless, it remains unknown how PKCδ regulates p66Shc during renal tubular cell injury. Our results do not show clear evidence for direct interaction of p66Shc by PKCδ. Thus, further studies are required to elucidate the protein interaction of PKCδ and p66Shc in the regulation of cell oxidative damage under HG ambience. It would be important to investigate in future to gain in-depth understanding of the regulation of tubular cell injury by PKCδ during the mitochondrial pathway.

In recent years, specific inhibitor of PKCδ has been reported to be used in many experimental models of DKD, which could effectively protect against kidney damage [41]. Moreover, it is currently the focus of clinical trials for several cardiovascular diseases and DKD [42, 43]. Hence, it would be also of great interest to investigate the effects of PKCδ inhibitors in DKD. However, studies have indicated that selective inhibitor of PKCδ, Rottlerin, was toxic to cells after a certain concentration [23], so large-scale clinical trials will need to validate safety and prospective application of Rottlerin in DKD.

In conclusion, this study has confirmed the increased activation of PKCδ as well as p66Shc during HG treatment of renal tubular cells in vitro and hyperglycemia in vivo. Under the experimental conditions, blockade of PKCδ pharmacologically or genetically can suppress HG-induced p66Shc phosphorylation and its mitochondrial translocation and protect the cells against oxidative damage. These data suggest that a novel PKCδ/p66Shc pathway may be involved in the pathogenesis of oxidative damage in diabetic kidney (Figure 8). Our results may also provide a new treatment strategy by targeting PKCδ for renoprotection in diabetic nephropathy or other oxidative stress diseases.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments
This work was supported by grants from the National Natural Sciences Foundation of China (81100541, 81270812, and 81470960), Doctoral Fund of Ministry of Education of China (2011162110012), and Furong Scholars Fund from Hunan Province Education.

References
[1] Y. S. Kanwar, L. Sun, P. Xie, E.-Y. Liu, and S. Chen, “A glimpse of various pathogenetic mechanisms of diabetic nephropathy,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 395–423, 2011.
[2] R. C. Stanton, “Clinical challenges in diagnosis and management of diabetic kidney disease,” American Journal of Kidney Diseases, vol. 63, supplement 2, no. 2, pp. S3–S21, 2014.
[3] G. J. Lau, N. Godin, H. Maachi et al., “Bcl-2-modifying factor induces renal proximal tubular cell apoptosis in diabetic mice,” Diabetes, vol. 61, no. 2, pp. 474–484, 2012.
[4] C. Velagapudi, B. S. Bhandari, S. Abboud-Werner, S. Simone, H. E. Abboud, and S. L. Habib, “The tuberin/mTOR pathway promotes apoptosis of tubular epithelial cells in diabetes,” Journal of the American Society of Nephrology, vol. 22, no. 2, pp. 262–273, 2011.
[5] M.-L. Brezniceanu, C. J. Lau, N. Godin et al., “Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 943–954, 2010.
[6] M. Morcos, A. A. R. Sayed, A. Bierhaus et al., “Activation of tubular epithelial cells in diabetic nephropathy,” Diabetes, vol. 51, no. 12, pp. 3532–3544, 2002.
[7] R. E. Gilbert and M. E. Cooper, “The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?” Kidney International, vol. 56, no. 5, pp. 1627–1637, 1999.
[8] M. Giorgio, E. Migliaccio, F. Orsini et al., “Electron transfer between cytochrome c and p66Sc generates reactive oxygen species that trigger mitochondrial apoptosis,” Cell, vol. 122, no. 2, pp. 221–233, 2005.
[9] A. M. Hall and R. J. Unwin, “The not so “mighty chondrion”: emergence of renal diseases due to mitochondrial dysfunction,” Nephron Physiology, vol. 105, no. 1, pp. 1–10, 2006.
[10] E. Migliaccio, M. Giorgio, S. Mele et al., “The p66sc adaptor protein controls oxidative stress response and life span in mammals,” Nature, vol. 402, no. 6759, pp. 309–313, 1999.
[11] I. Arany, A. Faisal, J. S. Clark, T. Vera, R. Baliga, and Y. Nagamine, “p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury,” The American Journal of Physiology—Renal Physiology, vol. 298, no. 5, pp. F1214–F1221, 2010.
[12] L. Sun, L. Xiao, J. Nie et al., “p66Shc mediates high-glucose and angiotensin II-induced oxidative stress renal tubular injury via mitochondrial-dependent apoptotic pathway,” The American Journal of Physiology—Renal Physiology, vol. 299, no. 5, pp. F1014–F1025, 2010.
[13] I. Arany, A. Faisal, Y. Nagamine, and R. L. Safirstein, “p66shc inhibits pro-survival epidermal growth factor receptor/ERK signaling during severe oxidative stress in mouse renal proximal tubule cells,” The Journal of Biological Chemistry, vol. 283, no. 10, pp. 6110–6117, 2008.
[14] P. Pinton, A. Rimessi, S. Marchi et al., “Protein kinase Cδ and prolyl isomerase I regulate mitochondrial effects of the life-span determinant p66Sc,” Science, vol. 315, no. 5812, pp. 659–663, 2007.
[15] U. Kikkawa, H. Matsuzaki, and T. Yamamoto, “Protein kinase Cδ (PKCδ): activation mechanisms and functions,” Journal of Biochemistry, vol. 132, no. 6, pp. 831–839, 2002.
[16] S. D. Persaud, V. Hoang, J. Huang, and A. Basu, “Involvement of proteolytic activation of PKCδ in cisplatin-induced apoptosis in human small cell lung cancer H69 cells,” International Journal of Oncology, vol. 27, no. 1, pp. 149–154, 2005.
[17] X. Qi, M. H. Disatnik, N. Shen, R. A. Sobel, and D. Mohly-Rosen, “Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo,” Molecular Biology of the Cell, vol. 22, no. 2, pp. 256–265, 2011.
[18] H. Wang, L. Xiao, and M. G. Kazanietz, “p23/Tmp21 associates with protein kinase Cδ (PKCδ) and modulates its apoptotic
function,” The Journal of Biological Chemistry, vol. 286, no. 18, pp. 15821–15831, 2011.
[19] M. Morita, H. Matsuzaki, T. Yamamoto, Y. Fukami, and U. Kikkawa, “Epidermal growth factor receptor phosphorylates protein kinase C δ at Tyr332 to form a trimeric complex with p66Shc in the H₂O₂-stimulated cells,” The Journal of Biochemistry, vol. 143, no. 1, pp. 31–38, 2008.
[20] Y. Haruna, N. Kashihara, M. Satoh et al., “Amelioration of progressive renal injury by genetic manipulation of Klotho gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 7, pp. 2331–2336, 2007.
[21] L. Sun, D. Zhang, F. Liu et al., “Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192,” Journal of Pathology, vol. 225, no. 3, pp. 364–377, 2011.
[22] L. Sun, S. Shukair, T. J. Naik, F. Moazed, and H. Ardehali, “Glucone phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II,” Molecular and Cellular Biology, vol. 28, no. 3, pp. 1007–1017, 2008.
[23] X. Li, N. Pabla, Q. Wei et al., “PKC-δ promotes renal tubular cell apoptosis associated with proteinuria,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1115–1124, 2010.
[24] D. Verzola, M. T. Gandolfò, F. Ferrario et al., “Apoptosis in the kidneys of patients with type II diabetic nephropathy,” Kidney International, vol. 72, no. 10, pp. 1262–1272, 2007.
[25] G. G. Camici, M. Schiavoni, P. Francia et al., “Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 12, pp. 5217–5222, 2007.
[26] A. A. Tomilov, V. Bicocca, R. A. Schoenfeld et al., “Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice,” Journal of Biological Chemistry, vol. 285, no. 2, pp. 1153–1165, 2010.
[27] H. Vashistha and L. Meggs, “Diabetic nephropathy: lessons from the mouse,” Ochsner Journal, vol. 13, no. 1, pp. 140–146, 2013.
[28] S. C. Ranieri, S. Fusco, E. Panieri et al., “Mammalian life-span determinant p66shc mediates obesity-induced insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 30, pp. 13420–13425, 2010.
[29] F. Paneni, P. Mocharla, A. Akhmedov et al., “Gene silencing of the mitochondrial adaptor p66Shc suppresses vascular hyperglycemic memory in diabetes,” Circulation Research, vol. 110, no. 3, pp. 278–289, 2012.
[30] Y. Shi, F. Cosentino, G. G. Camici et al., “Oxidized low-density lipoprotein activates p66shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase c-β, and c-jun n-terminal kinase in human endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 9, pp. 2090–2097, 2011.
[31] Z. Chen, G. Wang, X. Zhai et al., “Selective inhibition of protein kinase Gβ2 attenuates the adaptor P66Shc-mediated intestinal ischemia-reperfusion injury,” Cell Death and Disease, vol. 5, no. 4, Article ID e1164, 2014.
[32] S. Liu, Q. Yuan, S. Zhao et al., “High glucose induces apoptosis in embryonic neural progenitor cells by a pathway involving protein PKCδ,” Cellular Signalling, vol. 23, no. 8, pp. 1366–1374, 2011.
[33] R. Acin-Perez, B. Hoyos, J. Gong et al., “Regulation of intermediary metabolism by the PKCδ signalosome in mitochondria,” The FASEB Journal, vol. 24, no. 12, pp. 5033–5042, 2010.
[34] S. P. Davies, H. Reddy, M. Caivano, and P. Cohen, “Specificity and mechanism of action of some commonly used protein kinase inhibitors,” Biochemical Journal, vol. 351, no. 1, pp. 95–105, 2000.
[35] C. S. Lin, F. Y. Lin, L. J. Ho et al., “PKCδ signalling regulates SR-A and CD36 expression and foam cell formation,” Cardiovascular Research, vol. 95, no. 3, pp. 346–355, 2012.
[36] I. Talior, T. Tennenbaum, T. Kuroki, and H. Eldar-Finkelman, “PKC-δ-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 2, pp. E405–E411, 2005.
[37] M. Leitges, M. Mayr, U. Braun et al., “Exacerbated vein graft arteriosclerosis in protein kinase Cδ-null mice,” The Journal of Clinical Investigation, vol. 108, no. 10, pp. 1505–1512, 2001.
[38] C. L. Murriel, E. Churchill, K. Inagaki, L. I. Szweda, and D. Mochly-Rosen, “Protein kinase Cδ activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving bad and the mitochondria,” The Journal of Biological Chemistry, vol. 279, no. 46, pp. 47985–47991, 2004.
[39] E. N. Churchill and L. I. Szweda, “Translocation of δPKC to mitochondria during cardiac reperfusion enhances superoxide anion production and induces loss in mitochondrial function,” Archives of Biochemistry and Biophysics, vol. 439, no. 2, pp. 194–199, 2005.
[40] M. Leitges, K. Gimborn, W. Ellis et al., “Protein kinase Cδ is a negative regulator of antigen-induced mast cell degranulation,” Molecular and Cellular Biology, vol. 22, no. 12, pp. 3970–3980, 2002.
[41] D. Mochly-Rosen, K. Das, and K. V. Grimes, “Protein kinase C, an elusive therapeutic target?” Nature Reviews Drug Discovery, vol. 11, no. 12, pp. 937–957, 2012.
[42] L. P. Aiello, L. Vignati, M. J. Sheetz et al., “Oral protein kinase c-β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase c-β inhibitor-diabetic retinopathy study and the protein kinase c-β inhibitor-diabetic retinopathy study 2,” Retina, vol. 31, no. 10, pp. 2067–2094, 2011.
[43] K. R. Tuttle, J. B. McGill, D. J. Haney, T. E. Lin, and P. W. Anderson, “Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 631–636, 2007.